Sector Watch: Healthcare - Apr 30 2018
This is an archive page. To See the most recent Healthcare Sectorwatch click here
IBB: $103.65 -1.96 -1.86% | XBI: $86.98 -1.44 -1.63% | Updated Apr 30, 2018 04:26 PM
| HEALTHCARE STOCKS - TOP GAINERS | ||||
|---|---|---|---|---|
| STDY SteadyMed $127.2M |
4.70+2.05 1.3 M 48.1x |
77% | ||
| CHEK Check-Cap $217.5M |
12.79+3.77 4.9 M 9.0x |
42% | ||
| EBIO52WH Eleven Biotherapeutics $83.2M |
2.79+0.28 10.3 M 2.5x |
11% | ||
| IRMD52WH IRadimed $188.0M |
17.45+1.60 58.0 K 5.6x |
10% | ||
| AXSM Axsome Therapeutics $83.9M |
3.40+0.30 633.8 K 3.6x |
10% | ||
| HEALTHCARE STOCKS - TOP LOSERS | ||||
|---|---|---|---|---|
| KPTI Karyopharm Therapeutics $638.3M |
13.08-2.07 1.7 M 2.8x |
-14% | ||
| CFMS ConforMIS $81.5M |
1.29-0.16 1.5 M 3.2x |
-11% | ||
| AMPE Ampio Pharmaceuticals $219.8M |
2.59-0.30 754.3 K |
-10% | ||
| FATE Fate Therapeutics $552.5M |
10.10-1.11 694.9 K |
-10% | ||
| VTVT VTv Therapeutics $60.2M |
1.79-0.16 757.1 K |
-8% | ||
Not for trading - Data delayed up to 20 minutes from last update time.
Excludes companies with market caps below $50M.
Market Caps next to company names. Trading volumes below stock prices.
NNx - unusual volume NN times the 3-month avg. volume
52WL - 52-week Low in this trading session
52WH - 52-week High in this trading session
Healthcare Stocks Related News
United Therapeutics to Acquire SteadyMed Ltd. [globenewswire.com]SteadyMed (STDY) ALERT: Johnson Fistel Investigates Proposed Sale of SteadyMed Ltd.; Are [prnewswire.com]
SteadyMed (STDY) ALERT: Johnson Fistel Investigates Proposed Sale of SteadyMed Ltd.; Are Shareholders Getting a Fair Deal? [prnewswire.com]
Adicet Bio appoints Elizabeth ?EJ? Read, M.D. as Chief Technology Officer [prnewswire.com]
Adicet Bio appoints Elizabeth "EJ" Read, M.D. as Chief Technology Officer [prnewswire.com]
IRADIMED CORPORATION Announces First Quarter 2018 Financial Results [globenewswire.com]
Cardiome to Present at the Bloom Burton & Co. Healthcare Investor Conference [prnewswire.com]
Axsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression [globenewswire.com]
Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Depression, Alzheimer?s Disease Agitation, and Nicotine Dependence [globenewswire.com]
Axsome Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of AXS-05 in Smoking Cessation [globenewswire.com]
Preliminary Data from Phase 3 VISTA Trial in Bladder Cancer to Be Presented in a Plenary Session at American Urological Association Annual Meeting | Business Wire [businesswire.com]
Disclaimer Red Acre Investments is not a registered investment advisor and the views and opinions offered herein do not constitute investment advice. Investors should always conduct their own due diligence before trading. You should assume that Red Acre is trading the securities mentioned in our Red Acre Insights, generally in accordance with the views we express, although our positions may change as news evolves. We do not undertake any obligation to update our views as market conditions evolve.
